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Summary 
 
Tolerogenic dendritic cells (tolDC) are a new immunotherapeutic tool for the 
treatment of rheumatoid arthritis (RA) and other autoimmune disorders. We 
have established a method to generate stable tolDC by pharmacological 
modulation of human monocyte-derived DC. These tolDC exert potent pro-
tolerogenic actions on CD4+ T-cells. Lack of IL-12p70 production is a key 
immunoregulatory attribute of tolDC but does not fully explain their action. Here 
we show that tolDC express TGF-β1 at both mRNA and protein level, and that 
expression of this immunoregulatory cytokine is significantly higher in tolDC 
than in mature monocyte-derived DC. By inhibiting TGF-β1 signalling we 
demonstrate that tolDC regulate CD4+ T-cell responses in a manner that is at 
least partly dependent on this cytokine. Crucially, we also show that while there 
is no significant difference in expression of TGFβRII on CD4+ T-cells from RA 
patients and healthy controls RA patient CD4+ T-cells are measurably less 
responsive to TGF-β1 than healthy control CD4+ T-cells (reduced TGF-β-
induced Smad2/3 phosphorylation, FoxP3 expression and suppression of IFN-γ 
secretion). However, CD4+ T cells from RA patients can nonetheless be 
efficiently regulated by tolDC in a TGF-β1-dependent manner. This work is 
important for the design and development of future studies investigating the 
potential use of tolDC as a novel immunotherapy for the treatment of RA. 
Introduction 
 
Rheumatoid arthritis (RA) is a debilitating, chronic autoimmune disease 
resulting in joint inflammation and progressive joint destruction. It is thought that 
RA arises from a breakdown of immunological self-tolerance leading to aberrant 
immune responses to autoantigens. CD4+ T-cells, specifically Th1 and Th17 
cells, are thought to be the main contributors to this response via the production 
of proinflammatory cytokines, such as IFN-γ and IL-17A(1). There is currently 
no known cure for RA and current treatments involve chronic, non-antigen-
specific global immunosuppression, which can be associated with numerous 
side effects. New paradigms for the treatment of RA are focussed on the 
reinstatement of self-tolerance in an antigen-specific manner, leaving 
immunogenic responses to pathogen-derived antigens and cancer immunity 
intact. 
 
We have developed a novel, immunotherapeutic tool for inhibiting T-cell-
mediated pathology, namely tolerogenic dendritic cells (tolDC)(2-6). These cells 
are generated by treating monocyte-derived DC with the immunosuppressive 
glucocorticoid, dexamethasone (Dex); the vitamin D receptor agonist, vitamin 
D3 (VitD3); and the toll-like receptor 4 ligand, lipopolysaccharide (LPS). The 
phenotype of these cells is stable and is characterised by intermediate levels of 
the T-cell co-stimulatory molecules, CD80 and CD86, low levels of the 
proinflammatory cytokines, IL-12 and TNF-α, and high levels of the anti-
inflammatory cytokine, IL-10. We have demonstrated that equivalent murine 
tolDC can inhibit the destructive immune response in a collagen-induced 
arthritis (CIA) mouse model of RA(5), and we have recently completed a phase 
I clinical trial demonstrating the safety and feasibility of autologous tolDC 
therapy in inflammatory arthritis patients(7). tolDC have low immunostimulatory 
capacity for CD4+ T-cells. Specifically they skew naïve CD4+ T-cells responses 
to an anti-inflammatory profile, while they render memory CD4+ T-cells 
hyporesponsive(2-4). We have previously demonstrated that, despite the 
production of high levels of IL-10 by tolDC, this cytokine appears not to be 
essential for their regulatory action on CD4+ T cells, whereas deficient IL-12p70 
production is essential(2). 
 
TGF-β is a pleiotropic cytokine, produced by a wide variety of cells. Its most 
immunologically relevant and potent isoform is TGF-β1, which plays an 
important role in immunoregulation via direct suppression of T-cell proliferation 
and cytokine production(8) and the induction of FoxP3+ Tregs(9). TGF-β1 is 
produced in a latent inactive form through non-covalent linkage to latency-
associated peptide (LAP)(10). LAP(TGF-β1) can bind to the surface of cells, 
components of the extracellular matrix, or can exist in a soluble form. LAP(TGF-
β1) is activated (released from LAP) by a number of mechanisms, such as 
cleavage by thrombospondin. Activated TGF-β1 binds to TGF-β receptor II 
(TGF-βRII) followed by recruitment and activation of the primary signal 
transducer, TGF-βRI (ALK5). This leads to phosphorylation of the receptor-
regulated Smads, Smad2 and Smad3, that regulate target gene 
transcription(11). Negative feedback of the pathway is mediated by the 
inhibitory Smad, Smad7, which can either block or degrade TGF-βRI (12). 
 
TGF-β1 is abundant in the affected joints of RA patients(13-19) and increases 
with disease duration(20). However, this high level of TGF-β1 does not 
adequately regulate the pathogenic T-cell response in RA. This may be due to 
the overall proinflammatory cytokine environment in the synovium and the high 
level of T-cell activation, which are known to downregulate TGF-βRII 
expression(21, 22) or, alternatively, may be due to induction of inhibitory 
molecules, such as Smad7(23).  
 
We aimed to determine a potential role for TGF-β1 in the regulatory function of 
tolDC, and more specifically to investigate the ability of tolDC to regulate CD4+ 
T-cells from RA patients in a TGF-β1-dependent manner. A more complete 
understanding of the molecular mechanisms by which tolDC regulate T-cell 
responses is essential for the development of future studies on tolDC 
immunotherapy for RA. 
  
Materials and methods 
The minimum information about tolerogenic antigen-presenting cells (MITAP) 
checklist was followed for the preparation of this manuscript(24). See 
http://w3id.org/ontolink/mitap for MITAP document and checklist.  
 
Isolation of cells from peripheral blood and synovial fluid 
Human samples were obtained from healthy controls (HC) and patients with RA 
(disease duration over one year) with informed consent and following a 
favorable ethical opinion from South West 3 Research Ethics Committee. All 
samples were transported at room temperature and were processed within 3 h 
of sample retrieval. Peripheral blood mononuclear cells (PBMC) were isolated 
from 18 ml fresh EDTA anti-coagulated peripheral blood (PB) or 5 ml Leukocyte 
Reduction System cones by density centrifugation on Lymphoprep (Axis-Shield 
Diagnostics, Dundee, UK). Synovial fluid mononuclear cells (SFMC) were 
isolated from 10-50 ml synovial fluid (SF) by incubation with heparin (1 U/ml) 
and hyaluronidase (10 U/ml) for 30 minutes at 37°C before density 
centrifugation on Lymphoprep. CD14+ monocytes were isolated from HC PBMC 
by positive magnetic selection using anti-CD14 magnetic microbeads and a 
VarioMACS (both Miltenyi Biotec, Bergisch Gladbach, Germany). CD4+ T-cells 
were isolated from HC or RA PBMC with anti-CD4 magnetic microbeads 
(Miltenyi Biotec) or with RosetteSep CD4+ T-cell enrichment kit (StemCell 
Technologies, Vancouver, Canada). Purities of CD14+ monocytes and CD4+ T-
cells were routinely >90%, as determined by flow cytometry (data not shown). 
 
Generation of DC populations 
Freshly isolated monocytes were immediately cultured in RPMI-1640 (Sigma, 
Poole, UK) supplemented with 10% FCS (Lonza, Basel, Switzerland), 2 mM 
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (all from Sigma) at 
0.5x106 cells/ml in a 1 ml volume in a 24-well culture plate (costar, Corning, NY, 
USA)  in the presence of IL-4 and GM-CSF (50 ng/ml each, Immunotools, 
Friesoythe, Germany) for 7 days at 37oC with 5% CO2. Fresh pre-warmed 
medium and cytokines were added on day 3. Mature DC (matDC) were matured 
on day 6 by addition of LPS from Escherichia coli (0.1μg/ml, Sigma) for 24 h. 
tolDC were generated as above but with by addition of Dex (1x10-6 M, Sigma) at 
day 3 and Dex (1x10-6 M), the active form of vitD3, 1α,25-dihydroxyvitamin D3, 
(1x10-10 M, Leo-Pharma, Ballerup, Denmark) and LPS (0.1 μg/ml) at day 6 for 
24 h. On day 7 tolDC and matDC morphology was checked using an inverted 
microscope – tolDC were slightly elongated and adhered to the culture plates, 
whereas matDC were more rounded with visable dendrites and did not adhere 
to the culture plates. All DC populations were extensively washed before using 
them in functional assays. DC phenotype was checked using flow cytometry 
and was consistent with tolDC exhibiting a semi-mature phenotype, expressing 
low levels of CD83, intermediate levels of CD80 and CD86 and high levels of 
HLA-DR (data not shown). 
 
Micro Fluidic Cards 
RNA was extracted from DC using an RNeasy kit (Qiagen, Crawley, UK). RNA 
was reverse-transcribed to cDNA using random hexamers and SuperScript II 
RT (Invitrogen, Paisley, UK). cDNA samples were run on a custom Micro Fluidic 
Card (Applied Biosystems, Foster City, CA, USA) using an ABI Prism 7900HT 
system (Applied Biosystems). TGF-β1 mRNA expression was normalised to 
that of human GAPDH by subtracting the comparative threshold (CT) value of 
GAPDH from the CT value of TGF-β1 (∆CT). Results are expressed as 2-∆CT. 
 
Flow cytometry 
Anti-human LAP(TGF-β1)-PE antibody (27232; R&D Systems, Abingdon, UK) 
was used for cell surface marker analysis of DC. Anti-human CD3-APC (HIT3a; 
BD Bioscience, San Jose, CA, USA), CD4-FITC (RPA-T4; eBioscience Ltd., 
Hatfield, UK), and TGFβRII-PE (25508; R&D Systems) antibodies were used for 
cell surface marker analysis of PBMC and SFMC. Briefly, cells were centrifuged 
and resuspended in FACS buffer (PBS (Lonza) supplemented with 0.5% BSA 
(Sigma), 1mM EDTA (Fisher Scientific, Fair Lawn, New York, NY, USA), and 
0.01% sodium azide (Sigma)). 4g/ml human IgG (Grifols, Los Angeles, CA, 
USA), was added with antibodies to prevent Fc receptor binding. Cells were 
incubated on ice for 30 min, centrifuged and resuspended in FACS buffer. 
Intracellular FoxP3 was detected using a FoxP3-APC staining kit (PCH101; 
eBioscience). 
 
Intracellular pSmad2/3 was detected using a Phosflow assay by serum starving 
PBMC overnight by culture in serum-free X-VIVO 15 (Lonza) at 37oC with 5% 
CO2. PBMC were stimulated with 10 ng/ml TGF-β1 (PeproTech, EC Ltd., 
London, UK) for 30 minutes at 37oC. Untreated control samples were set-up in 
parallel. PBMC were fixed using 1X BD Phosflow Lyse/Fix Buffer (BD 
Bioscience) and then permeabilised using BD Perm Buffer III (BD Bioscience). 
To reduce background staining the cells were blocked with 2% mouse serum 
(Sigma) for 15 min prior to addition of anti-human CD3-Pacific Blue (UCHT-1; 
BD Bioscience), Smad2 (pS465/pS467)/Smad3 (pS423/pS425)-PE (pSmad2/3; 
O72-670; BD Bioscience) and CD4-APC-eFluor780 (SK3; eBioscience) 
antibodies. PBMC were incubated at room temperature for 1 h, centrifuged and 
resuspend in stain buffer (PBS with Ca2+ and Mg2+ (Lonza) supplemented with 
0.2% BSA and 0.09% sodium azide). Data was collected on a BD FACSCanto II 
(BD Biosciences) and analysed using FlowJo (Tree Star Inc.). Results are 
shown as either the median fluorescent intensity (MFI) of the marker of interest 
or as a percentage of cells expressing the marker of interest. 
 
Stimulation of cells by αCD3αCD28 expander beads and TGF-β1 
PBMC, SFMC and CD4+ T-cells were stimulated with αCD3αCD28 expander 
beads (10:1 ratio; Dyna, Invitrogen) in the absence or presence of 10 ng/ml 
TGF-β1 in RPMI-1640 supplemented with 10% FCS, 2 mM glutamine, 100 U/ml 
penicillin and 100 μg/ml streptomycin. Supernatants were harvested after 3 
days and assayed for IFN-γ by sandwich ELISA (BD Bioscience). Percentage 
suppression was calculated as follows: ([amount of cytokine in absence of TGF-
β – amount of cytokine in presence of TGF-β] / amount of cytokine in absence 
of TGF-β) × 100. The percentage of CD4+FoxP3+ cells was determined by flow 
cytometry. 
 
DC-T-cell co-cultures 
1x104 DC were cultured with 1x105 allogeneic CD4+ T-cells (1:10 ratio) in 200μl 
serum-free X-VIVO 15 medium (Lonza). TGFβRI (ALK5) inhibitor (SB-505124; 
Sigma) or recombinant human LAP (R&D Systems) was added where 
indicated. Supernatants were harvested after 6 days and assayed for IFN-γ and 
IL-17A by sandwich ELISA and other cytokines by an immunoassay (MSD, 
Maryland, USA). Proliferation was assessed by incorporation of 3H-thymidine 
for the last 8 h of culture by scintillation counting (Microbeta TriLux, Perkin 
Elmer, USA). 
 
T-cell restimulation 
Allogeneic CD4+ T-cells were primed with DC (1:10) in the presence or absence 
of 1μM SB-505124 for 6 days and rested for 4 days with 10 IU/ml IL-2 
(Proleukin; Novartis Pharmaceuticals UK Ltd., Surrey, UK). No residual DC 
were observed in the T-cell lines. Primed T-cells were washed and restimulated 
with matDC from the original DC donor (1:10) in serum-free X-VIVO 15 medium 
(Lonza). Supernatants were harvested after 72 h and assayed for IL-10 (BD 
Bioscience) and IFN-γ by sandwich ELISA. Cultures were pulsed with 3H-
thymidine for a further 8 hours to determine proliferation. 
 
Statistics 
Wilcoxon signed rank tests or Mann Whitney tests were performed using Prism 
4.0 (GraphPad Software). All p values are two-tailed. 
  
Results 
 
tolDC express TGF-β1 
To investigate the role of TGF-β1 in tolDC function we began by measuring the 
expression of TGF-β1 in tolDC and matDC populations. tolDC expressed more 
TGFB1 mRNA than matDC (Figure 1A). To confirm that TGFB1 transcripts were 
translated, we used flow cytometry to assess TGF-β1 protein expression on the 
cell surface using an anti-LAP(TGF-β1) antibody. Mirroring the transcript data, 
LAP(TGF-β1) was expressed at a higher level on the surface of tolDC as 
compared to matDC (Figure 1B). Together, these data show that tolDC express 
a higher level of TGF-β1 than matDC at both mRNA and protein level.  
 
TGF-β1 is involved in tolDC regulatory function 
We next determined the role of TGF-β1 in the regulatory action of tolDC. 
Allogeneic HC CD4+ T-cells were co-cultured with DC in the presence or 
absence of SB-505124, a small molecule inhibitor of TGF-βRI. In keeping with 
our previous finding(4), tolDC showed a reduced ability to induce T-cell 
proliferation and IFN-γ production in CD4+ T-cells as compared with matDC 
(Figure 2A-B). Importantly, addition of SB-505124 had no effect on T-cell 
proliferation but enhanced the production of IFN-γ by tolDC-primed T-cells in a 
dose-dependent manner - restoring levels to those produced by control cells 
(matDC-primed T cells)(Figure 2A-B). The effect of blocking TGF-β1 signalling 
in a primary MLR using 1μM SB-505124 results in a 2.7 fold increase in IFN-γ 
production from matDC-CD4+ T cell cultures (data not shown) and a 46.5 fold 
increase in IFN-γ production from tolDC-CD4+ T cell cultures (summary of data 
shown in Figure 2B). Blocking TGF-β signalling with SB-505124 also enhanced 
IL-4 and IL-10 cytokine production, with minimal effect on IL-2, TNF-α, IL-17A, 
IL-6, IL-1-β, IL-8 and IL-13 production, by tolDC-primed T-cells, although this 
was not as pronounced as the effect seen for IFN-γ production (Figure 2C). We 
repeated the experiment using a different TGF-β signalling inhibitor, 
recombinant LAP, which binds and sequesters active TGF-β1. Although LAP 
was less potent, similar effects were demonstrated (Figure 2D). The effects of 
blocking TGF-β signalling with SB-505124 were also observed at a lower DC:T 
cell ratio of 1:20 and 1:40 (Supplementary Figure 1). 
 
We further investigated whether blockade of the TGF-β signalling pathway 
could overcome the regulatory effects of tolDC on CD4+ T-cells that are evident 
on T cell restimulation. As we have shown previously(4), HC CD4+ T-cells 
primed by tolDC (Ttol) have significantly reduced cytokine production upon 
restimulation as compared to matDC-primed CD4+ T-cells (Tmat) (Figure 2E). 
Importantly, addition of 1μM SB-505124 during priming significantly reversed 
the inhibition of IFN-γ and IL-10 production by tolDC to control levels (Figure 2E 
and Supplementary Figure 2). These data indicate that part of the regulatory 
activity of tolDC, specifically the ability of tolDC to suppress cytokine production 
by CD4+ T-cells, is dependent on TGF-β1 signalling. 
 
HC and RA CD4+ T-cells express TGF-βRII but RA CD4+ T-cells are less 
responsive to TGF-β1 
Proinflammatory cytokines and high levels of T cell activation, both features of 
RA, can induce downregulation of TGF-βRII expression(21, 22) and induce 
expression of inhibitory molecules, such as Smad7(23). These may render RA 
T-cells resistant to regulation by TGF-β1.  To investigate this, we first 
determined the expression of TGF-βRII on the surface of HC T-cells from PB 
and RA T-cells from both PB and SF. We found no significant difference in the 
percentage of CD4+ T-cells expressing TGF-βRII between HC PB T cells and 
RA PB or SF T cells, although the trend was for a reduced proportion of TGF-
βRII+ CD4+ T-cells in RA T cells (Figure 3A). 
 
We next examined whether HC and RA PBMC responded differently to TGF-β1 
by testing the ability of TGF-β1 to suppress production of IFN-γ by the cells. The 
extent of suppression of IFN-γ by TGF-β1 in PBMC and SFMC from RA patients 
was lower than in PBMC from HC (Figure 3B and Supplementary Figure 3). We 
also demonstrated a trend for fewer FoxP3-expressing CD4+ T-cells from RA 
patients than from HC following stimulation of T-cells in the presence of TGF-β 
(Figure 3C). This suggests that PBMC and SFMC from RA patients have a 
reduced regulatory response to TGF-β. To further explore the ability of RA T-
cells to respond to TGF-β1 we used a Phosflow assay to measure the level of 
phospho-Smad2/3 (pSmad2/3) in CD4+ T cells following TGF-β1 stimulation. 
CD4+ T-cells from RA PB had significantly lower pSmad2/3 levels following 
TGF-β1 stimulation as compared to HC CD4+ T-cells from PB (Figure 3D). 
These data suggest that CD4+ T-cells from RA patients have a reduced ability 
to respond to TGF-β1. 
 RA CD4+ T-cells can be regulated by tolDC in a TGF-β-dependent manner 
Our work demonstrates that TGF-β1 is involved in the regulatory function of 
tolDC and is responsible for inducing a hyporesponsive phenotype in CD4+ T-
cells. As RA T-cells appear to have a reduced response to TGF-β1 we next 
investigated whether these cells can be tolerised by tolDC. Similar to the 
findings in HC, tolDC showed a reduced ability to induce T-cell proliferation and 
production of IFN-γ in RA CD4+ T-cells as compared with matDC (Figure 4). 
Unlike the result seen in HC CD4+ T-cells (Figure 2B), addition of SB-505124 to 
RA CD4+ T-cell-tolDC co-cultures induced a small increase in T-cell 
proliferation, although this was not restored to the levels of the control cells 
(matDC-primed T cells) and the effect of SB-505124 was very subtle. 
Interestingly, addition of SB-505124 to these cultures did enhance the 
production of IFN-γ by tolDC-primed T-cells, restoring levels to those of the 
control cells (matDC-primed T cells). These data suggest that CD4+ T-cells from 
RA patients can be regulated by tolDC partly via a TGF-β1 dependent 
mechanism. Interestingly, Smad7 was found to be expressed in RA patient 
CD4+ T-cells, however it was also expressed in CD4+ T-cells from a proportion 
of HC (Supplementary Figure 4). In addition, there was a trend for increased 
TGF-βRII expression on CD4+ T-cells cultured with tolDC (Supplementary 
Figure 5).  
Discussion 
 
This study focussed on the role of TGF-β in the regulatory function of tolDC. We 
have found that tolDC express TGF-β1 and this cytokine is involved in their 
ability to regulate T-cells. TGF-β1 expression by tolDC is an important functional 
characteristic for the regulation of cytokine production by T-cells and plays a 
role in reducing both IFN-γ and IL-10 production in tolDC-primed CD4+ T-cells. 
However, TGF-β1 does not seem to play a major role in the inhibition of T-cell 
proliferation. Importantly, despite the reduced ability of CD4+ T-cells from RA 
patients to respond to TGF-β1 these cells are still regulated by tolDC in a TGF-
β1 dependent manner. 
 
We previously investigated the effect of blocking TGF-β1 signalling in tolDC-T-
cell co-cultures and demonstrated that the use of a TGF-β1 neutralising 
antibody (1D11, R&D Systems) had no effect on the regulatory action of 
tolDC(2). The discrepancy between the results with the neutralising antibody 
and those shown here using the ALK5 inhibitor SB-505124, or LAP, may be 
explained by the concentration of neutralising antibody used being insufficient to 
inhibit the amount of TGF-β1 produced by tolDC. In addition, FCS, which 
contains high levels of TGF-β1, was added to the culture medium in the original 
experiments. This may have led to sequestration of the neutralising antibody, 
thus interfering with efforts to neutralise TGF-β1 in those assays. 
 
We report that TGF-β1 has differential effects on CD4+ T-cell proliferation and 
cytokine production: there was no effect on proliferation but potent inhibition of 
cytokine production. TGF-β1 can have both stimulatory and inhibitory effects on 
T-cell proliferation and differentiation depending on the differentiation stage of 
the cells and the cytokine microenvironment. It has been reported that TGF-β1 
can inhibit resting CD4+ T-cell proliferation and cytokine production but has no 
inhibitory effect on activated T-cells, due to downregulation of TGF-βRII(22). 
Addition of IL-10 enhanced TGF-βRII expression and restored TGF-β1 
responsiveness in activated T-cells, although we have been unable to 
reproduce this result (data not shown). Interestingly, tolDC increase TGF-βRII 
expression on CD4+ T-cells, although the mechanism inducing this upregulation 
requires further investigation. Other factors involved in the proliferative 
response of T-cells to TGF-β1 include CD28 co-stimulation(25). In the absence 
of CD28 co-stimulation, TGF-β1 inhibits proliferation of naïve T-cells but in the 
presence of CD28 co-stimulation it enhances proliferation. A similar effect of 
CD28 co-stimulation was not observed in memory/effector cells, as TGF-β1 
enhanced their proliferation, whether co-stimulation was present or not. Our 
tolDC express intermediate levels of the co-stimulatory molecules CD80 and 
CD86, which ligate CD28 on T-cells. Therefore, the differential effect of TGF-β1 
on CD4+ T-cell proliferation and cytokine production reported here could be due 
to a combination of the cytokine microenvironment and the co-stimulatory 
capacity of our tolDC. 
 
The importance of intact TGF-β signalling in RA T-cells is demonstrated by the 
fact that disruption of TGF-β signalling in T-cells in a CIA murine model leads to 
exacerbation of arthritis, which is associated with increased Th1 cytokines, IFN-
γ and TNF-α(26). We have demonstrated that RA PBMC and SFMC have a 
reduced ability to respond to TGF-β1, as demonstrated by a reduced level of 
suppression of IFN-γ production following stimulation in the presence of TGF-
β1. This is in keeping with published literature that exogenous TGF-β1 cannot 
inhibit the spontaneous cytokine production of RA synovial mononuclear cells in 
culture(27) and cannot reduce IFN-γ production by RA synovial T-cells(28). In 
addition, we have shown that stimulation of RA CD4+ T-cells with TGF-β1 
induces less FoxP3 expression and less pSmad2/3 induction compared to cells 
from HC. A similar result has been reported in RA PBMC, which had deficient 
TGF-β1 signalling, evidenced by reduced levels of pSmad2/3(29). 
 
This reduced response to TGF-β1 does not appear to be linked to a reduced 
level of TGF-βRII expression. The immune environment found in RA may 
explain the diminished response of RA T-cells to TGF-β1. For example, the 
proinflammatory cytokine TNF-α, which is found in high levels in RA PB and SF, 
can regulate TGF-β signalling via the induction of inhibitory Smad7(23) and via 
AP-1 components that interfere with Smad signalling(30). Indeed, we found 
expression of Smad7 in RA CD4+ T cells. Thus, the defective response to TGF-
β1 in these cells may be due to increased negative feedback via Smad7. 
Defective TGF-β signalling has also been demonstrated in T-cells from other 
inflammatory conditions, including systemic lupus erythematosus and Crohn’s 
disease (31, 32). In the latter case, defective TGF-β1-signalling was due to 
expression of high levels of Smad7, which could be reversed with treatments 
targeting this molecule(32, 33). Whether tolDC can override the negative 
regulatory Smad7 loop by, for example, increasing the expression of TGF-βRII 
on CD4+ T-cells (Supplementary Figure 5) and enhancing the level of Smad2/3-
mediated signalling will require further investigation.  
 
In conclusion, tolDC regulate T-cell cytokine production via expression of TGF-
β1. Despite RA T-cells having a reduced response to TGF-β1 regulation, tolDC 
are still capable of regulating the cytokine response of RA T-cells. Thus tolDC 
may be a promising tool for the restoration of immune tolerance in RA. 
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Figure legends 
 
Figure 1: tolDC express TGF-β. (A) Expression of the TGF-β1 gene by matDC 
and tolDC was measured using a custom Micro Fluidic Card (Applied 
Biosystems). mRNA expression was normalised to that of human GAPDH by 
subtracting the CT value of the gene of interest from the CT value of the human 
GAPDH gene (CT). Results are expressed as 2-CT for 4 independent 
experiments. Horizontal lines represent median values. (B) matDC and tolDC 
were stained with anti-human LAP(TGF-β1) antibody and were assessed by 
flow cytometry. Debris and dead cells were excluded on the basis of forward-
scatter and side-scatter. Left panel shows one representative plot of 10 
independent donors. Right panel shows the MFI for LAP(TGF-β1) expression. 
Horizontal lines represent median values. N = 10. ** p < 0.01 calculated with 
Wilcoxon signed rank test. 
 
Figure 2: TGF-β1 diminishes the ability of tolDC to stimulate HC T-cells 
and is involved in their regulatory function. (A-D) matDC or tolDC (1x104 
cells/well) were co-cultured with allogeneic HC CD4+ T-cells (1x105 cells/well) in 
the absence or presence of increasing concentrations of SB-505124, a small 
molecule inhibitor of TGF-βRI (A) or 1μM SB-505124 (B-C) or increasing 
concentrations of recombinant LAP (D). Proliferation (A, B and D left panels), 
measured using 3H-thymidine uptake, and IFN-γ production (A, B and D right 
panels), measured using ELISA, were assessed at day 6. (C) Additional 
cytokines were detected in day 6 culture supernatants from tolDC-CD4+ T-cell 
cultures using an ELISA (IL-17A) or MSD immunoassay (all others). The fold 
change in cytokine production following inhibition of TGF-β1 signalling was 
calculated by: concentration of cytokine produced in the presence of 1μM SB-
505124 ÷ concentration of cytokine produced in the absence of 1μM SB-
505124. IL-17A was undetectable in one experiment. Error bars in A and D 
represent SEM of triplicates (proliferation) or duplicates (IFN-γ production). 
Horizontal lines in B and C represent median values, B left panel (proliferation) 
n = 7; B right panel (IFN-γ production) n = 15; C (cytokines) n =3. (E) Allogeneic 
HC CD4+ T-cells were primed with DC (1:10) for 6 days and rested for 4 days 
with 10 IU/ml IL-2. T-cell lines primed by matDC (Tmat), tolDC (Ttol) and tolDC 
+ SB-505124 (Ttol-SB) were restimulated with matDC and IFN-γ (left panel) and 
IL-10 (right panel) production, measured using ELISA, was assessed on day 3. 
Results are depicted as the percentage cytokine production of Tmat cell lines. 
Cytokine concentrations range: IFN-γ in Ttol = 0.9 – 20.6 ng/ml and in Ttol-SB = 
4.4 – 80.7 ng/ml; IL-10 in Ttol = 0.4 – 5.1 ng/ml and in Ttol-SB = 0.9 – 31.7 
ng/ml. Horizontal lines represent median values, n (IFN-γ production) = 7; n (IL-
10 production) = 6. * p< 0.05 and *** p < 0.0001  calculated with Wilcoxon 
signed rank test. # represent significant differences (p < 0.05) between Ttol and 
Tmat cells. 
 
Figure 3: HC and RA CD4+ T-cells express TGF-βRII but RA CD4+ T-cells 
have a reduced response to TGF-β1 stimulation. PBMC or CD4+ T-cells 
were isolated from the PB of HC or RA patients and SFMC were isolated from 
SF of RA patients. (A) Cells were stained with anti-human CD3, anti-human 
CD4, and anti-human TGF-βRII antibodies and were assessed by flow 
cytometry. Debris and dead cells were excluded on the basis of forward-scatter 
and side-scatter. A CD3+CD4+ gate was used to identify CD4+ T-cells. 
Representative plots of TGF-βRII expression on CD4+ T-cells (left panel). The 
gate shows the percentage of CD4+ T-cells expressing TGF-βRII. The 
percentage of CD4+ T-cells expressing TGF-βRII (right panel). Horizontal lines 
represent median values. N (HC PB) = 21, n (RA PB) = 16, n (RA SF) = 5. (B) 
PBMC from HC (n=6) and PBMC  (▼) and SFMC (●) from RA patients (n=5) 
were stimulated with αCD3αCD28 beads in the absence or presence of 10 
ng/ml TGF-β1 for 3 days. IFN-γ was measured by ELISA and percentage 
suppression was calculated as follows: ([cytokine in absence of TGF-β – 
cytokine in presence of TGF-β]/ cytokine in absence of TGF-β) × 100. IFN-γ 
concentrations range in cultures without TGF-β1: HC = 1.1 – 32.4 ng/ml and RA 
patients = 0.7 – 32.2 ng/ml; and in cultures with TGF-β1: HC = 0.1 – 5.3 ng/ml 
and RA patients = 0.5 – 79.1 ng/ml. (C) CD4+ T-cells from HC PB (n=6) and RA 
patient PB (n=4) were stimulated with αCD3αCD28 beads in the presence of 10 
ng/ml TGF-β1 for 3 days. The percentage of CD4+FoxP3+ was determined by 
flow cytometry. (D) PBMC were left unstimulated or were stimulated with 10 
ng/ml TGF-β1 for 30 minutes before being fixed and permeabilised. PBMC were 
blocked with 2% mouse serum and stained with anti-human CD3, anti-human 
CD4 and anti-human pSmad2/3 antibodies before assessment by flow 
cytometry. Debris and dead cells were excluded on the basis of forward-scatter 
and side-scatter. A CD3+CD4+ gate was used to identify CD4+ T-cells. 
Representative plots of pSmad2/3 expression on CD4+ T-cells in unstimulated 
and stimulated conditions (left panel). Fold induction of pSmad2/3 in CD4+ T-
cells following TGF-β1 stimulation calculated by dividing the MFI of stimulated 
cells by the MFI of unstimulated cells (right panel). Horizontal lines represent 
median values. N = 6. * p < 0.05 and ** p < 0.01  calculated using a Mann 
Whitney test. 
 
Figure 4: RA CD4+ T-cells can be regulated by tolDC in a TGF-β-dependent 
manner. CD4+ T-cells (1x105 cells/well) from RA patients were co-cultured with 
allogenic matDC or tolDC (1x104 cells/well) from a healthy control in the 
absence or presence of 1μM SB-505124, a small molecule inhibitor of TGF-βRI. 
Proliferation (left panel), measured using 3H-thymidine uptake, and IFN-γ 
production (right panel), measured using ELISA, were assessed at day 6. N = 
18. Horizontal lines represent median values. ** p < 0.01 and *** p < 0.0005 
calculated with Wilcoxon signed rank test. 
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Supplementary Figure 1: TGF-β1 diminishes the ability of tolDC to stimulate HC T-cells at
different DC: T cell ratios. matDC or tolDC were co-cultured with allogeneic HC CD4+ T-cells (1x105
cells/well) at different DC: T cell ratios in the absence or presence of 1μM SB-505124, a small molecule
inhibitor of TGF-βRI. Proliferation (A), measured using 3H-thymidine uptake, and IFN-γ production (B),
measured using a MSD immunoassay, were assessed at day 6. Columns represent median values for n
= 3.
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Supplementary Figure 2: Cytokine concentrations in restimulation assays. Allogeneic HC CD4+
T-cells were primed with DC (1:10) for 6 days and rested for 4 days with 10 IU/ml IL-2. T-cell lines
primed by matDC (Tmat), tolDC (Ttol) and tolDC + SB-505124 (Ttol-SB) were restimulated with
matDC and IFN-γ (A) and IL-10 (B) production, measured using ELISA, was assessed on day 3.
Horizontal lines represent median values, n (IFN-γ production) = 7; n (IL-10 production) = 6. * p< 0.05
calculated with Wilcoxon signed rank test. Figure 2E shows these results depicted as the percentage
cytokine production of Tmat cell lines.
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Supplementary Figure 3: RA CD4+ T-cells have a reduced
response to TGF-β1 stimulation. PBMC from HC (n=6) and PBMC
and SFMC from RA patients (n=5) were stimulated with αCD3αCD28
beads in the absence or presence of 10 ng/ml TGF-β1 for 3 days. IFN-
γ was measured by ELISA. Horizontal lines represent median values. *
p < 0.05 calculated using a Wilcoxon signed rank test. Figure 3B
shows these results depicted as the percentage suppression of
cultures containing TGF-β1 compared to those without.
Supplementary Figure 4: RA CD4+ T-cells express Smad7. CD4+ T-cells from HC (n=4) and RA patients (n=6) were isolated
and lysed in RIPA buffer before analysis using western blot. Blots were probed with anti-human Smad7 (clone 293039; R&D
systems – MW 50KDa) and anti-human GAPDH (clone D16H11; Cell Signalling – MW 37KDa). HeLa cell lysate was used as a
positive control.
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Supplementary Figure 5: tolDC induce TGFβRII expression on T-cells. CD4+ T-cells (1x106 cells/well) were co-cultured
with allogeneic tolDC (1x105 cells/well) for 1 day, 3 days or 6 days. Cells were stained with anti-human CD3, anti-human
CD4, and anti-human TGF-βRII antibodies and were assessed by flow cytometry. Debris and dead cells were excluded on
the basis of forward-scatter and side-scatter. A CD3+CD4+ gate was used to identify CD4+ T-cells. (A) Representative plots
of TGF-βRII expression on CD4+ T-cells. The gate shows the percentage of CD4+ T-cells expressing TGF-βRII. (B) The
percentage of CD4+ T-cells expressing TGF-βRII at the different time-points. Bars represent median values for n = 3.
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